This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Neurology  • Deep Brain Stimulation  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Günther Deuschl, MD, PhD

JAMA. 2009;301(1):104-105.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The treatment of advanced stages of Parkinson disease (PD) is a major challenge for modern medicine. This devastating movement disorder is characterized by severe fluctuations of the patient's mobility between a state of sometimes complete akinesia and dyskinetic hypermobility often being equally bothersome for the patient. These symptoms frequently are accompanied by wide fluctuating nonmotor symptoms such as anxiety, depression, hallucinations, and autonomic disturbances. While the early stages of PD usually can be sufficiently treated, this condition presents an ongoing therapeutic problem. After the revolutionary discovery of levodopa as the most efficient drug therapy¹ during the early stages of the disease, it has been found that long-term complications limit the use of this drug.² The great hope for transplantation of embryonic cells to restore endogenous L-dopa production was met with initial success³ but has turned into a disappointment, with 2 double-blind studies demonstrating lack of efficacy . . . [Full Text of this Article]

Author Affiliation: Department of Neurology, Universitätsklinikum Schleswig-Holstein, Kiel Campus, Kiel, Germany.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial
Frances M. Weaver, Kenneth Follett, Matthew Stern, Kwan Hur, Crystal Harris, William J. Marks, Jr, Johannes Rothlind, Oren Sagher, Domenic Reda, Claudia S. Moy, Rajesh Pahwa, Kim Burchiel, Penelope Hogarth, Eugene C. Lai, John E. Duda, Kathryn Holloway, Ali Samii, Stacy Horn, Jeff Bronstein, Gatana Stoner, Jill Heemskerk, Grant D. Huang, and for the CSP 468 Study Group
JAMA. 2009;301(1):63-73.
ABSTRACT | FULL TEXT